(ADGM) Adagio Medical Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

ADGM: Cryocatheters, Ablation, Catheters, Accessories

Adagio Medical Holdings, Inc. (NASDAQ:ADGM) is a developmental-stage medical device company specializing in innovative ablation technologies for treating cardiac arrhythmias. Its product portfolio includes the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories, designed for precise and efficient treatment of atrial fibrillation and flutter. The company also offers the vCLAS ventricular ULTC catheter for addressing ventricular tachycardia, alongside the Cryopulse atrial pulsed-field cryoablation catheter and accessories. Founded in 2011 and headquartered in Laguna Hills, California, Adagio Medical Holdings focuses on advancing cryoablation technologies to improve outcomes for patients with cardiac arrhythmias. The companys approach combines ultra-low temperature cryoablation with pulsed-field technology, aiming to provide safer and more effective treatments compared to traditional methods.

Based on the provided data, the 3-month forecast for Adagio Medical Holdings, Inc. (NASDAQ:ADGM) suggests the following trends: - Technical Outlook: The stock is currently trading below its 20-day and 50-day simple moving averages (SMA), indicating bearish momentum. The 200-day SMA of 2.67 suggests a potential long-term downtrend. Average trading volume of 178,188 shares over 20 days and an ATR of 0.16 indicate moderate volatility. - Fundamental Outlook: With a market cap of $54.65M and a price-to-sales ratio of 205.44, the stock is priced at a premium relative to its revenue. The return on equity (RoE) of 0.56% reflects limited profitability. Given the developmental stage of the company and the absence of P/E and forward P/E ratios, investors should focus on operational progress and potential catalysts in the near term. - Price Forecast: Based on technical and fundamental factors, the stock is expected to trade in a range of $0.90 to $1.35 over the next three months, with potential resistance at the 50-day SMA of 1.12 and support at the ATR-based lower bound of $0.91.

Additional Sources for ADGM Stock

ADGM Stock Overview

Market Cap in USD 55m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2024-08-01

ADGM Stock Ratings

Growth 5y -46.1%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -86.4
Analysts -
Fair Price Momentum 1.05 USD
Fair Price DCF -

ADGM Dividends

No Dividends Paid

ADGM Growth Ratios

Growth Correlation 3m -10.9%
Growth Correlation 12m -92.3%
Growth Correlation 5y -92.3%
CAGR 5y -86.78%
CAGR/Max DD 5y -0.96
Sharpe Ratio 12m -1.21
Alpha -85.47
Beta -0.85
Volatility 145.19%
Current Volume 11.6k
Average Volume 20d 80.5k
What is the price of ADGM stocks?
As of March 15, 2025, the stock is trading at USD 1.08 with a total of 11,593 shares traded.
Over the past week, the price has changed by +1.89%, over one month by -16.28%, over three months by -40.98% and over the past year by -86.78%.
Is Adagio Medical Holdings a good stock to buy?
Probably not. Based on ValueRay Analyses, Adagio Medical Holdings (NASDAQ:ADGM) is currently (March 2025) not a good stock to buy. It has a ValueRay Growth Rating of -46.08 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADGM as of March 2025 is 1.05. This means that ADGM is currently overvalued and has a potential downside of -2.78%.
Is ADGM a buy, sell or hold?
Adagio Medical Holdings has no consensus analysts rating.
What are the forecast for ADGM stock price target?
According to ValueRays Forecast Model, ADGM Adagio Medical Holdings will be worth about 1.1 in March 2026. The stock is currently trading at 1.08. This means that the stock has a potential upside of +5.56%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1.1 5.6%